Exact Mass: 603.3536004

Exact Mass Matches: 603.3536004

Found 39 metabolites which its exact mass value is equals to given mass value 603.3536004, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Janthitrem E

8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,24-dioxa-31-azaoctacyclo[15.14.0.0²,¹⁵.0³,¹².0⁶,¹¹.0¹⁸,³⁰.0²⁰,²⁸.0²²,²⁷]hentriaconta-1(17),10,18(30),19,26,28-hexaene-9,12,21-triol

C37H49NO6 (603.3559694)


Janthitrem E is produced by Penicillium janthinellum. Tremorgenic mycotoxi Production by Penicillium janthinellum. Tremorgenic mycotoxin.

   

Benzonatate

2-[2-[2-[2-[2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoic acid

C30H53NO11 (603.3618428)


Benzonatate is a non-narcotic oral antitussive (cough suppressant) drug which works by anesthetizing the tissues of the lungs and pleura responsible for the cough reflex. It is chemically related to other ester anesthetics such as procaine. It has an anesthetic (numbing) action similar to that of benzocaine and numbs the stretch sensors in the lungs. It is the stretching of these sensors with breathing that causes the cough. It was approved by the FDA in 1958. R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents

   

Fumonisin AK1

1,2,3-Propanetricarboxylic acid, 1-[13-(acetylamino)-5,10,12-trihydroxy-3-methyl-1-(2-methyl-1-oxohexyl)tetradecyl] ester

C30H53NO11 (603.3618428)


Fumonisin AK1 is produced by Fusarium proliferatum. Production by Fusarium proliferatum.

   

PC(2:0/20:3(6,8,11)-OH(5))

(2-{[(2R)-3-(acetyloxy)-2-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H54NO9P (603.3536004)


PC(2:0/20:3(6,8,11)-OH(5)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

PC(20:3(6,8,11)-OH(5)/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H54NO9P (603.3536004)


PC(20:3(6,8,11)-OH(5)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:3(6,8,11)-OH(5)/2:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

   

Benzonatate

benzonatate (2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl p-(butylamino)-benzoate

C30H53NO11 (603.3618428)


R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents

   

Janthitrem E

8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,24-dioxa-31-azaoctacyclo[15.14.0.0^{2,15}.0^{3,12}.0^{6,11}.0^{18,30}.0^{20,28}.0^{22,27}]hentriaconta-1(17),10,18,20(28),26,29-hexaene-9,12,21-triol

C37H49NO6 (603.3559694)


   

Fumonisin AK1

2-{2-[(19-acetamido-11,16,18-trihydroxy-5,9-dimethyl-6-oxoicosan-7-yl)oxy]-2-oxoethyl}butanedioic acid

C30H53NO11 (603.3618428)


   
   

8-[2-((2S)-4-Hydroxy-1-{[5-(hydroxymethyl)-6-methoxy-2-naphthyl]methyl}-6-oxopiperidin-2-YL)ethyl]-3,7-dimethyl-1,2,3,7,8,8A-hexahydronaphthalen-1-YL 2-methylbutanoate

8-[2-((2S)-4-Hydroxy-1-{[5-(hydroxymethyl)-6-methoxy-2-naphthyl]methyl}-6-oxopiperidin-2-YL)ethyl]-3,7-dimethyl-1,2,3,7,8,8A-hexahydronaphthalen-1-YL 2-methylbutanoate

C37H49NO6 (603.3559694)


   

[(2R)-3-acetyloxy-2-[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[(2R)-3-acetyloxy-2-[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C30H54NO9P (603.3536004)


   

[(2R)-2-acetyloxy-3-[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[(2R)-2-acetyloxy-3-[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C30H54NO9P (603.3536004)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

PS P-20:1/4:1 or PS O-20:2/4:1

PS P-20:1/4:1 or PS O-20:2/4:1

C30H54NO9P (603.3536004)


   
   

PS P-24:2 or PS O-24:3

PS P-24:2 or PS O-24:3

C30H54NO9P (603.3536004)


   
   

8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,24-dioxa-31-azaoctacyclo[15.14.0.0²,¹⁵.0³,¹².0⁶,¹¹.0¹⁸,³⁰.0²⁰,²⁸.0²²,²⁷]hentriaconta-1(17),10,18,20(28),26,29-hexaene-9,12,21-triol

8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,24-dioxa-31-azaoctacyclo[15.14.0.0²,¹⁵.0³,¹².0⁶,¹¹.0¹⁸,³⁰.0²⁰,²⁸.0²²,²⁷]hentriaconta-1(17),10,18,20(28),26,29-hexaene-9,12,21-triol

C37H49NO6 (603.3559694)


   

(2s,3r,6s,8s,9r,12s,15s,21r,22s)-8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,24-dioxa-31-azaoctacyclo[15.14.0.0²,¹⁵.0³,¹².0⁶,¹¹.0¹⁸,³⁰.0²⁰,²⁸.0²²,²⁷]hentriaconta-1(17),10,18,20(28),26,29-hexaene-9,12,21-triol

(2s,3r,6s,8s,9r,12s,15s,21r,22s)-8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,24-dioxa-31-azaoctacyclo[15.14.0.0²,¹⁵.0³,¹².0⁶,¹¹.0¹⁸,³⁰.0²⁰,²⁸.0²²,²⁷]hentriaconta-1(17),10,18,20(28),26,29-hexaene-9,12,21-triol

C37H49NO6 (603.3559694)


   

(1's,2s,3r,12's,15's,20'r)-15'-hydroxy-3-[(2s,4r,5r)-5-hydroxy-6,6-dimethyl-2-(2-methylprop-1-en-1-yl)-1,3-dioxan-4-yl]-1',20'-dimethyl-8'-(3-methylbut-2-en-1-yl)-3'-azaspiro[oxirane-2,16'-pentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosane]-2'(10'),4',6',8'-tetraen-17'-one

(1's,2s,3r,12's,15's,20'r)-15'-hydroxy-3-[(2s,4r,5r)-5-hydroxy-6,6-dimethyl-2-(2-methylprop-1-en-1-yl)-1,3-dioxan-4-yl]-1',20'-dimethyl-8'-(3-methylbut-2-en-1-yl)-3'-azaspiro[oxirane-2,16'-pentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosane]-2'(10'),4',6',8'-tetraen-17'-one

C37H49NO6 (603.3559694)


   

15'-hydroxy-3-[5-hydroxy-6,6-dimethyl-2-(2-methylprop-1-en-1-yl)-1,3-dioxan-4-yl]-1',20'-dimethyl-8'-(3-methylbut-2-en-1-yl)-3'-azaspiro[oxirane-2,16'-pentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosane]-2'(10'),4',6',8'-tetraen-17'-one

15'-hydroxy-3-[5-hydroxy-6,6-dimethyl-2-(2-methylprop-1-en-1-yl)-1,3-dioxan-4-yl]-1',20'-dimethyl-8'-(3-methylbut-2-en-1-yl)-3'-azaspiro[oxirane-2,16'-pentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosane]-2'(10'),4',6',8'-tetraen-17'-one

C37H49NO6 (603.3559694)